Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Valentis (VLTS) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (39)	1/9/2001 7:18:37 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 81

tuck, I'm not much of a source for deep understanding on this or anything. mz pointed out not long ago that shearwater offers a more complete service package with its peg-technology which may explain its success in recent 'wins'. It is discouraging, all the other pegggers, liposomers, sphere-aters, timerexers...but the point vlts makes is that, for protein therapeutics, polymasc has a successful track record of successful peg attachment without loss of effectiveness. Of course we will learn a lot more this year. Anyway, I sold my enzn (I originally bit on the sca technology, but it looks like its either not so popular or not being exploited) to get involved here. To my knowledge, the peg-IP dispute is between branched/unbranched interferon peggers, not involving vlts...but I am now going to rush to edgar to make sure I didn't miss this in vlts's documents...I have sure thought all along that polymasc is quite owned and protected by vlts. Wilder